Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
Anisha B PatelSahira FarooqMacartney WelbornRodabe N AmariaSusan Y ChonAdi DiabIsabella C Glitza OlivaAuris O HuenShirley Q LiKelly C NelsonOmar PachaSapna Pradyuman PatelRonald P RapiniHussein A TawbiMichael K WongJennifer McQuadeMichael A DaviesLauren E HayduPublished in: Cancer (2021)
CAEs were mostly reversible and rarely required therapy discontinuation. The development of CAEs was associated with a longer TTNT, and this suggested a possible clinical benefit.
Keyphrases